Finance

Senarai
600535:SHA
Tasly Pharmaceutical Group Co Ltd
CN¥14.22
+0.14%
(+0.020) 1H
12 Okt, 3:00:03 PTG GMT+8  ·   CNY
Semua simbol
SimbolHargaPerubahan% Perubahan
Menjana cerapan popular untuk 600535...
Buka
CN¥14.21
Tinggi
CN¥14.33
Rendah
CN¥14.13
Permodalan Pasaran
21.21B
Purata volum
12.30J
Volum
10.14J
Dividen
2.39%
Dividen suku tahunan
CN¥0.09
Tarikh tanpa dividen
29 Mei 2026
Nisbah H/P
17.37
tgi 52 mgu
CN¥16.24
rdh 52 mgu
CN¥12.90
EPS
CN¥0.82
Syer tertunggak
1.51B
Bilangan pekerja
11K
Buka
CN¥14.21
Tinggi
CN¥14.33
Rendah
CN¥14.13
Permodalan Pasaran
21.21B
Purata volum
12.30J
Volum
10.14J
Dividen
2.39%
Dividen suku tahunan
CN¥0.09
Tarikh tanpa dividen
29 Mei 2026
Nisbah H/P
17.37
tgi 52 mgu
CN¥16.24
rdh 52 mgu
CN¥12.90
EPS
CN¥0.82
Syer tertunggak
1.51B
Bilangan pekerja
11K
Cerita berita
Daripada sumber web dan rakan kongsi berita
Profil
Tasly is a Chinese pharmaceutical company based in the city of Tianjin. It was established in 1994 and is notably producing traditional Chinese medicines. It has a turnover of 4 billion US dollars, 10,000 employees and is listed on the Shanghai Stock Exchange. In 2009, Chinese pharmacologist Li Lianda claimed that a key product made by Tasly was unsafe. Tasly sued Li in 2013, alleging that Li's claim was baseless and was motivated by his financial and employment relations with Guangzhou Pharmaceutical, a direct competitor of Tasly. In September 2014, the Tianjin High People's Court ruled in favour of Tasly and ordered Li to issue an apology and pay Tasly 300,000 yuan in compensation. In February 2017, Tasly announced plans to form a joint venture with American multi-level marketing company Herbalife. Wikipedia
Perihal Tasly Pharmaceutical Group Co Ltd
CEO-
Pekerja10.6K
Diasaskan1994
Ibu pejabat-
Sektor-
Laman webtasly.com
Laporan sebelumnyaSemua nilai dalam CNY
Loading Previous Earnings...
Hasil
Pendapatan bersih
Semua nilai dalam CNY
Sep 2025
Dis 2025
Mac 2026
Jun 2026
Hasil
2.02B
1.93B
2.16B
2.04B
Kos barangan yang dijual
684.07J
659.71J
623.69J
654.28J
Kos hasil
684.07J
659.71J
623.69J
654.28J
Perbelanjaan penyelidikan dan pembangunan
210.48J
132.23J
191.62J
102.48J
Jumlah perbelanjaan penyelidikan dan pembangunan
-
-
-
-
Perbelanjaan jualan, am dan pentadbiran
844.05J
787.37J
874.15J
656.33J
Belanja kendalian
1.06B
979.15J
1.08B
801.23J
Jumlah belanja kendalian
1.74B
1.64B
1.70B
1.46B
Pendapatan kendalian
281.20J
286.94J
462.71J
580.75J
Pendapatan bukan kendalian lain
-7.57J
-6.11J
-733.75K
-232.24K
EBT termasuk item luar biasa
248.13J
192.46J
461.52J
584.82J
EBT tidak termasuk item luar biasa
280.97J
289.16J
472.69J
588.33J
Belanja cukai pendapatan
45.36J
123.68J
96.97J
64.84J
Kadar cukai berkesan
18.28%
64.26%
21.01%
11.09%
Belanja kendalian lain
1.56J
53.20J
17.23J
42.82J
Pendapatan bersih
209.68J
120.59J
370.24J
522.44J
Margin untung bersih
10.37%
6.26%
17.10%
25.66%
Perolehan bagi setiap syer
-
-
-
-
Pendapatan faedah dan pelaburan
14.77J
14.84J
14.04J
11.58J
Belanja faedah
-7.28J
-5.44J
-3.33J
-5.30J
Belanja faedah bersih
7.49J
9.39J
10.71J
6.29J
Caj susut nilai dan pelunasan
-
-
-
-
EBITDA
380.28J
380.23J
555.99J
663.57J
Keuntungan atau kerugian daripada jualan aset
5.21J
-8.61J
-
-409.04K
Kandungan AI boleh mengandungi kesilapan. Ketahui lebih lanjut
BantuanHantar maklum balasPrivasiSyaratPenafian
Apl Google